HR 1503
116th Congress
House
Health
Administrative law and regulatory procedures
Congressional oversight
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Government information and archives
Intellectual property
Prescription drugs
Orange Book Transparency Act of 2019
Everywhere this bill has been
30 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 5, 2021
Became Public Law No: 116-290.
Jan 5, 2021
Signed by President.
Dec 24, 2020
Presented to President.
Dec 10, 2020
Mrs. Dingell asked unanimous consent to take the bill, H.R. 1503 from the Speaker's Table and agree to the Senate amendment. (consideration: CR H7130-7131)
Dec 10, 2020
Mrs. Dingell asked unanimous consent that the House agree to the Senate amendment.
Dec 10, 2020
On motion that the House agree to the Senate amendment Agreed to without objection. (text: CR H7130-7131)
Dec 10, 2020
Motion to reconsider laid on the table Agreed to without objection.
Dec 10, 2020
Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to without objection.(text: CR H7130-7131)
Dec 8, 2020
Message on Senate action sent to the House.
Dec 7, 2020
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7242-7243)
Dec 7, 2020
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S7242-7243)
Dec 7, 2020
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
Dec 7, 2020
Measure laid before Senate by unanimous consent. (consideration: CR S7244)
May 9, 2019
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 8, 2019
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 422 - 0 (Roll no. 187). (text: CR H3486-3487)
May 8, 2019
Motion to reconsider laid on the table Agreed to without objection.
May 8, 2019
Considered as unfinished business. (consideration: CR H3491)
May 8, 2019
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
May 8, 2019
DEBATE - The House proceeded with forty minutes of debate on H.R. 1503.
May 8, 2019
Considered under suspension of the rules. (consideration: CR H3486-3488)
May 8, 2019
Ms. Eshoo moved to suspend the rules and pass the bill, as amended.
May 2, 2019
Placed on the Union Calendar, Calendar No. 25.
May 2, 2019
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-47.
Apr 3, 2019
Ordered to be Reported (Amended) by Voice Vote.
Apr 3, 2019
Committee Consideration and Mark-up Session Held.
Mar 27, 2019
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Mar 27, 2019
Subcommittee Consideration and Mark-up Session Held.
Mar 6, 2019
Referred to the Subcommittee on Health.
Mar 5, 2019
Referred to the House Committee on Energy and Commerce.
Mar 5, 2019
Introduced in House
Votes taken on this bill
1
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| May 8, 2019 | House · vote #187 | On Motion to Suspend the Rules and Pass, as Amended | Passed | 422–0 | See who voted → |
Amendments to this bill
1
Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.
1 agreed to
| Amendment | Sponsor | Status |
|---|---|---|
| SAMDT 2,693 | — | Agreed to |
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Orange Book Transparency Act of 2020
This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded.The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.
What's happening now
Became Public Law No: 116-290.
Related & companion bills
1
Bill text
7 versions
- Engrossed Amendment Senate Formatted Text PDF Formatted XML
- Engrossed in House Formatted Text PDF Formatted XML
- Enrolled Bill Formatted Text PDF Formatted XML
- Introduced in House Formatted Text PDF Formatted XML
- Public Law Formatted Text PDF United States Legislative Markup
- Referred in Senate Formatted Text PDF Formatted XML
- Reported in House Formatted Text PDF Formatted XML
Committees of jurisdiction
3
Cite this page
U.S. Congress. (2026). H.R. 1503: Orange Book Transparency Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-1503/
"H.R. 1503: Orange Book Transparency Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-1503/.
H.R. 1503, 116th Cong. (2026), https://openamerica.io/bill/116-HR-1503/.
[H.R. 1503: Orange Book Transparency Act of 2020](https://openamerica.io/bill/116-HR-1503/)